Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
nadunolimab (CAN04)
i
Other names:
CAN04, CAN-04, anti-il-1rap mab
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(1)
News
Trials
Company:
Cantargia
Drug class:
IL1RAP inhibitor
Related drugs:
‹
BOS-371 (0)
BOS-371 (0)
›
Associations
(1)
News
Trials
Search handles
@MPishvaian
Search handles
@MPishvaian
Filter by
Latest
almost2years
Will you discuss Cantargia’s ph2 in NSCLC? They have an abstract at #ASCO22 with their IL1RAP antibody Nadunolimab in combination with chemotherapy that looks really promising, especially in Non-Squamos and patients previously treated with Keytruda ORR 88% (@FrillePelle)
almost 2 years ago
Clinical • Combination therapy
|
IL1RAP (Interleukin 1 Receptor Accessory Protein)
|
Keytruda (pembrolizumab) • nadunolimab (CAN04)
almost2years
#ASCO22 #PancreaticCancer 🔥Promising new💊 ✅Dr. Van Custem🧑🏫a Ph1/2 trial of an anti-IL1RAP mAb, nadunolimab + gem-nab-pac ➡️73 efficacy assessable pts ➡️mOS – 13.2 mos ➡️But ORR only 33% 🔎Poster🗣️Session Abst 4141, Poster 11 (@MPishvaian)
almost 2 years ago
Clinical
|
IL1RAP (Interleukin 1 Receptor Accessory Protein)
|
nadunolimab (CAN04)
almost2years
”knockdown or pharmacologic inhibition of IL1RAP pathways can result in growth inhibition in pancreatic cancer cells” Suprised that @Aiims1742 and @Amitvermamds didn’t mention Cantargia’s IL1RAP antibody CAN04 Check out the ph2 PDAC update at ASCO 😉 https://t.co/2ZXUBucxBI (@FrillePelle)
almost 2 years ago
IL1RAP (Interleukin 1 Receptor Accessory Protein)
|
nadunolimab (CAN04)
almost2years
Cantargia's antibody Nadunolimab targeting IL1RAP is involved in three different abstracts including oral presentation at ASCO Their study TRIFOUR evaluates nadunolimab combined with chemo in TNBC TNBC expresses IL1RAP at higher levels compared to other types of breast cancer. (@FrillePelle)
almost 2 years ago
IL1RAP (Interleukin 1 Receptor Accessory Protein)
|
nadunolimab (CAN04)
almost2years
Cantargia's antibody Nadunolimab targeting IL1RAP is involved in three different abstracts including oral presentation. Update on their encouraging ph2 data in chemo combinations in both NSCLC & PDAC Early efficacy data in combination with Pembrolizumab in solid tumours. (@FrillePelle)
almost 2 years ago
Clinical • Combination therapy
|
IL1RAP (Interleukin 1 Receptor Accessory Protein)
|
Keytruda (pembrolizumab) • nadunolimab (CAN04)
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login